- Home
- FAX vs PCRX Comparison
FAX vs PCRX Comparison
Compare FAX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | PCRX |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.9M | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FAX | PCRX |
|---|---|---|
| Price | $15.52 | $25.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 833.6K | ★ 869.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ N/A | $55.29 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $2.33 | $18.17 |
| 52 Week High | $2.84 | $27.64 |
Technical Indicators
Market Signals| Indicator | FAX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 58.53 |
| Support Level | $15.20 | $25.56 |
| Resistance Level | $15.75 | $26.70 |
| Average True Range (ATR) | 0.11 | 0.93 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 72.98 | 57.67 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.